Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04355039
Other study ID # IIT-Dhakal-INCB053914
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date July 1, 2021
Est. completion date July 1, 2024

Study information

Verified date August 2020
Source Medical College of Wisconsin
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, single-center, open-label phase Ib study aimed at determining a recommended phase II dose of INCB053914 and pomalidomide with dexamethasone. The trial will follow a 3 + 3 phase I dose-escalation design.


Description:

This is a prospective, single-center phase I clinical study aimed at determining the maximum-tolerated dose and safety of INCB053914 (pan-PIM kinase inhibitor) and pomalidomide with dexamethasone in patients with relapsed and/or refractory multiple myeloma. Three candidate dose levels of INCB053914, 50 mg, 65 mg, and 80 mg twice daily will be considered.

The research team will utilize a 3+3 design to determine a safe dose of INCB053914 combined with fixed doses of pomalidomide (4 mg Days 1- Days 21) and dexamethasone (40 mg Days 1, 8, 15, 22).

The first three patients will be treated with INCB053914 twice daily at a dose of 50 mg.

Dose-limiting toxicity (DLT) assessment during the first 28-day cycle will be the basis for maximum-tolerated dose assessment.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date July 1, 2024
Est. primary completion date July 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

2. Patient should have received =2 lines of therapy including at least two consecutive cycles of lenalidomide and a proteasome inhibitor alone or in combination and should be relapsed and/or refractory to lenalidomide and a proteasome inhibitor.

3. Measurable disease as defined (at least one of the following):

- Serum M-protein level =0.5 g/dl or urine M-protein level =200 mg/24 hours. OR

- Light chain multiple myeloma without measurable disease in the urine: serum Ig free light chain (FLC) =10 mg/dL and abnormal serum Ig kappa/lambda FLC ratio.

- Non-secretory multiple myeloma (MM) with bidimensionally measurable plasmacytoma.

4. Male or female subjects =18 years.

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

6. Female subjects must meet one of the following:

- Postmenopausal for at least one year before enrollment, OR

- Surgically sterile (i.e., undergone a hysterectomy or bilateral oophorectomy), OR

- If subject is of childbearing potential (defined as not satisfying either of the above two criteria), agrees to practice two acceptable methods of contraception (combination methods require use of two of the following: diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male or female condom, hormonal contraceptive) from the time of signing of the informed consent form through 21days after the last dose of study agent, OR o Agrees to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable contraception methods.)

7. Male subjects, even if surgically sterilized (i.e., status postvasectomy), must agree to one of the following:

Practice effective barrier contraception during the entire study period and through 90 calendar days after the last dose of study agent, OR

o Agrees to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post ovulation methods] and withdrawal are not acceptable methods of contraception.)

Exclusion Criteria:

1. Prior use of PIM kinase inhibitors.

2. Prior pomalidomide refractory patients (last prior therapy was pomalidomide-containing regimen and/or patients within three months of pomalidomide dose).

3. Diagnosed or treated for malignancy other than multiple myeloma, except:

- Malignancy treated with curative intent and with no known active disease present for =2 years before enrollment.

- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.

- Adequately treated carcinoma in situ (e.g., cervical, breast) with no evidence of disease.

4. Exhibiting clinical signs of meningeal or central nervous system involvement by multiple myeloma.

5. Known to be seropositive for human immunodeficiency virus, known to have hepatitis B surface antigen positivity, or known to have a history of hepatitis C.

6. Concurrent medical condition or disease (e.g., active systemic infection) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study. Specifically, any potential subject who is unsuitable for autologous stem cell transplant (ASCT) would be excluded from the study.

7. Clinically significant cardiac disease, including:

- Myocardial infarction within six months before Cycle 1, Day 1, or unstable or uncontrolled disease/condition related to or affecting cardiac function (e.g., unstable angina, congestive heart failure, New York Heart Association Class III-IV).

- Uncontrolled cardiac arrhythmia (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] Version 5 grade 2 or higher) or clinically significant electrocardiogram (ECG) abnormalities.

- Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) >470 msec.

8. Any of the following laboratory test results during the screening phase:

- Absolute neutrophil count <1.0 × 109/L; no granulocyte-colony stimulating factor (G-CSF) treatment in the past seven days are allowed.

- Hemoglobin level =7.5 g/dL (=5 mmol/L); blood transfusions to maintain hemoglobin >7.5 g/dL are acceptable.

- Platelet count <50 × 109/L for subjects in whom <50% of bone marrow nucleated cells are plasma cells; otherwise platelet count <50 × 109/L; no platelet transfusions in the past seven days are allowed.

Study Design


Intervention

Drug:
Pomalidomide
4 mg Days 1-21
Dexamethasone
40 mg Days 1, 8, 15 and 22
INCB053914 50 mg bis in die (BID)
Dose level 0: 50 mg BID
INCB053914 65 mg BID
Dose level 1: 65 mg BID
INCB053914 80 mg BID
Dose level 2: 80 mg BID

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Medical College of Wisconsin

Outcome

Type Measure Description Time frame Safety issue
Primary The number of subjects with dose-limiting toxicities. The safety of INCB053914 with pomalidomide and dexamethasone in participants with relapsed and/or refractory multiple myeloma. 28 days
Secondary The recommended phase II dose of INCB053914. Based on number of dose-limiting toxicities. 28 days
Secondary Progression-free survival. This measure is the number of months participants remain free from evidence of disease. This will be captured using International Myeloma Working Group criteria. 2 Years
Secondary Overall survival. Overall survival is defined from the number of months from initiation of treatment until death due to any cause. Participants without an observed progression / death event will be censored at the last follow-up or end of study. 2 Years
Secondary Duration of response. The number of months from the date of first documented response (complete or partial) to the time of the next relapse/progression. This will be captured using International Myeloma Working Group criteria. 2 Years
Secondary Efficacy of bone protective effect of INCB053914 in combination with pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma. The number of subjects with negative serum C terminal telopeptide type-X (CTX). This is determined by a blood draw. 7 months
Secondary The bone protective effect of INCB053914 in combination with pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma. The number of subjects with positive serum N terminal propeptide of procollagen (P1NP). This is determined by a blood draw. 7 months
Secondary The number of subjects with reduction of osteolytic lesions. This will be determined by positron emission tomography (PET) /MRI scans, using RECIST. 7 months
Secondary The number of subjects with reduction of sclerosis formation. This will be determined by positron emission tomography (PET) /MRI scans, using RECIST. 7 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04083534 - First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) Phase 1/Phase 2
Terminated NCT02020941 - Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy Phase 2
Completed NCT01775553 - Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib Phase 2
Completed NCT01212952 - Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Terminated NCT01078441 - Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant Phase 2
Completed NCT01233921 - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer N/A
Completed NCT00514137 - Sunitinib in Treating Patients With Relapsed Multiple Myeloma Phase 2
Completed NCT00306813 - Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT00078858 - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Phase 1/Phase 2
Completed NCT00047203 - Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 2
Active, not recruiting NCT03731832 - Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma Phase 2
Completed NCT00003196 - Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma N/A
Recruiting NCT03601624 - Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans Phase 2
Terminated NCT01954784 - Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma Phase 1
Recruiting NCT05020444 - TriPRIL CAR T Cells in Multiple Myeloma Phase 1
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Recruiting NCT04302324 - A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab Phase 2
Recruiting NCT06119685 - IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers Phase 1/Phase 2
Completed NCT00118170 - Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function Phase 1
Completed NCT00054353 - Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma Phase 1/Phase 2